Antitumor activity of rituximab plus thalidomide in patients with relapsed/refractory mantle cell lymphoma - Wikidata - awgldk - TriplyDB

Antitumor activity of rituximab plus thalidomide in patients with relapsed/refractory mantle cell lymphoma

Antitumor activity of rituximab plus thalidomide in patients with relapsed/refractory mantle cell lymphoma

http://www.wikidata.org/entity/Q28263800

about

Intensive therapies for mantle cell lymphoma: time for a disease-specific approach?Low-dose, single-agent temsirolimus for relapsed mantle cell lymphoma: a phase 2 trial in the North Central Cancer Treatment Group Durable responses with the metronomic rituximab and thalidomide plus prednisone, etoposide, procarbazine, and cyclophosphamide regimen in elderly patients with recurrent mantle cell lymphoma.Bortezomib combined with rituximab and dexamethasone is an active regimen for patients with relapsed and chemotherapy-refractory mantle cell lymphoma.Phase II Study of Bortezomib in Combination with Cyclophosphamide and Rituximab for Relapsed or Refractory Mantle Cell Lymphoma.Electroacupuncture for thalidomide/bortezomib-induced peripheral neuropathy in multiple myeloma: a feasibility study.Thalidomide plus chemotherapy exhibit enhanced efficacy in the clinical treatment of T-cell non-Hodgkin's lymphoma: A prospective study of 46 cases.Temsirolimus in the treatment of relapsed or refractory mantle cell lymphoma.Mantle cell lymphoma: biology, pathogenesis, and the molecular basis of treatment in the genomic era Updated survival analysis of two sequential prospective trials of R-MACLO-IVAM followed by maintenance for newly diagnosed mantle cell lymphoma.Relapsed and/or Refractory Mantle Cell Lymphoma: What Role for Temsirolimus?Mantle cell lymphoma of the larynx: Primary case report.Treatment of mantle cell lymphoma: targeting the microenvironment.Monoclonal antibody therapy of leukaemias and lymphomas.Long-term results of the treatment of patients with mantle cell lymphoma with cladribine (2-CDA) alone (95-80-53) or 2-CDA and rituximab (N0189) in the North Central Cancer Treatment Group.Immunomodulatory drugs.Therapy with bortezomib plus lenalidomide for relapsed/refractory mantle cell lymphoma: final results of a phase II trial (CALGB 50501)The role of angiogenesis in human non-Hodgkin lymphomas.Novel therapeutic targets in mantle cell lymphoma.The expanding role of rituximab and radioimmunotherapy in the treatment of B-cell lymphomas.Therapeutic options in mantle cell lymphoma.Angiogenesis and antiangiogenic therapy in non-Hodgkin's lymphoma Thalidomide enhanced the efficacy of CHOP chemotherapy in the treatment of diffuse large B cell lymphoma: A phase II study.Molecular outcome prediction in mantle cell lymphoma.Yttrium ibritumomab tiuxetan in the treatment of non-Hodgkin's lymphoma: current status and future prospects.Mantle cell lymphoma: state-of-the-art management and future perspective.Lenalidomide inhibits lymphangiogenesis in preclinical models of mantle cell lymphoma Immunomodulating antibodies and drugs for the treatment of hematological malignancies.Current status of targeted therapies for mantle cell lymphoma.Update on the molecular pathogenesis and clinical treatment of mantle cell lymphoma: report of the 11th annual conference of the European Mantle Cell Lymphoma Network.Emerging agents for the treatment of mantle cell lymphoma.Management of mantle cell lymphoma in the elderly: current and potential strategies.Lenalidomide in relapsed or refractory mantle cell lymphoma: overview and perspective.Are we a step forward with targeted agents in resolving the enigma of mantle cell lymphoma?Stat3 inhibition augments the immunogenicity of B-cell lymphoma cells, leading to effective antitumor immunity.Molecular action of lenalidomide in lymphocytes and hematologic malignancies Should there be a standard therapy for mantle cell lymphoma?A rare case of leukemic presentation of blastoid variant of mantle cell lymphoma with isolated splenic involvement: Flowcytometric revelation.How I treat mantle cell lymphoma.Novel therapies for aggressive B-cell lymphoma

P2860

Q24299054-1AEFECC1-D654-4497-A8D6-816D5DB2A066 Q33379949-94BE660F-FFF6-4AF5-9351-0F9E51225D6E Q33388648-A0B12D72-247F-4989-ADCF-857DB3681278 Q33394873-8B5B1514-D517-4935-B191-4FC637DDE97B Q33440979-A7CC341C-A77D-4FF2-8B8C-17933A7F2363 Q33684190-88B1E91A-BCFB-42C1-9C10-3AD8105965AD Q33932989-8C494B51-CEDC-417B-A2D2-4D3D738AAF61 Q34129360-21AEF844-3986-4A22-8862-15C6A3A87599 Q34568868-CB8CDE90-E2CE-4132-B816-BC2E8826D0C9 Q35629679-E4CA672A-1594-42EF-8317-61A8F2C18ECF Q35835983-8574A67F-2A6D-4B8E-BE80-FBB7BE27D1E3 Q36150574-30239EF1-6028-4745-8AAD-04AC730D5892 Q36185624-08CCFC6C-7B0E-418E-B5CC-A8784B5A776A Q36239669-273CF513-648A-4308-BE0B-D06A0FE11412 Q36301583-9443B159-7D7B-43AB-A457-98872B0BF33E Q36321396-9E62EFFC-094D-4A44-B87F-6760A744BD86 Q36498968-8C425FFD-673A-4D77-9472-DBE5A5AD2C38 Q36670881-27666449-9882-4622-9AC1-402257015F67 Q36871990-5A7B3B5A-90E9-4559-8951-2EC0B23A2C46 Q36981694-41DEFBDC-8036-407C-87FE-0531323639D2 Q37093669-DD360C42-9A91-4646-A981-19011924F327 Q37321798-06CAD933-3A83-4E0B-9889-3BE3C807812C Q37362916-308E949A-15D4-4287-BB56-C7ADA4C67751 Q37401338-6E08B510-098C-4D47-829C-36FB6A34B84E Q37586857-A14AC6EF-B5DF-4169-A700-A46CA3C76919 Q37622873-043EEC3A-9A15-460C-84F5-FF77CC93582C Q37626685-C00F700C-C5C5-4F25-B299-7344935AA493 Q37832694-2DC30242-AC96-41DC-AEED-918634A85974 Q37956405-0B773FC5-AC79-4F61-85FE-6C1656B8E319 Q38047385-FD98EDE8-3A53-48ED-A7FE-13D0D36D3459 Q38055498-D906FC63-5D41-4516-A894-2EB34BCCCDA3 Q38157682-8BCADD32-D5A4-410E-A643-FCFD5718B531 Q38216650-CED17F2C-5129-4C26-BF78-4F6073F2C648 Q38382492-5B817B5B-DA0E-47A1-B312-5BF91E2040E2 Q38810148-336A359B-D06B-4705-AD32-2272C86EBC9A Q39570166-A19E9CE5-FB3A-4755-843C-F812263575E0 Q39779748-4B2F065F-2C2E-4B45-B4A3-E5715C239CA5 Q41769063-949BD192-8F49-475B-AC0C-14387B252CB3 Q41988762-1D7BBF6E-BA10-4987-B6CA-4426B77B7ECC Q42011578-22C9573A-CE85-4BD3-9297-BC42D66060EE

P2860

Antitumor activity of rituximab plus thalidomide in patients with relapsed/refractory mantle cell lymphoma

http://www.wikidata.org/entity/Q28263800

description

2004 nî lūn-bûn

@nan

2004 թուականի Հոկտեմբերին հրատարակուած գիտական յօդուած

@hyw

2004 թվականի հոտեմբերին հրատարակված գիտական հոդված

@hy

2004年の論文

@ja

2004年論文

@yue

2004年論文

@zh-hant

2004年論文

@zh-hk

2004年論文

@zh-mo

2004年論文

@zh-tw

2004年论文

@wuu

name

Antitumor activity of rituxima ...... efractory mantle cell lymphoma

@ast

Antitumor activity of rituxima ...... efractory mantle cell lymphoma

@en

Antitumor activity of rituxima ...... efractory mantle cell lymphoma

@nl

type

label

Antitumor activity of rituxima ...... efractory mantle cell lymphoma

@ast

Antitumor activity of rituxima ...... efractory mantle cell lymphoma

@en

Antitumor activity of rituxima ...... efractory mantle cell lymphoma

@nl

prefLabel

Antitumor activity of rituxima ...... efractory mantle cell lymphoma

@ast

Antitumor activity of rituxima ...... efractory mantle cell lymphoma

@en

Antitumor activity of rituxima ...... efractory mantle cell lymphoma

@nl

P1433

Q28263800-A3EF6753-31CB-4D2B-8319-D6D5827C78C3

P1476

Q28263800-F5AEF380-DBDE-494D-962B-6D794C60F553

P2093

Q28263800-388717FB-579E-4188-931B-662D9871870C

Q28263800-6A762338-51DC-43AD-894D-4DEE7A146F8C

Q28263800-869EDD01-C77B-4A8C-8CD9-4AE30E2F5750

Q28263800-99103429-09F0-4E41-BE4C-7E4EDD641B46

Q28263800-B00B780E-32E1-40B0-A310-FBDA310CB17F

Q28263800-C0D418FE-9191-4C18-9372-1BF51BD21A24

Q28263800-CADEE697-C0DA-4C9F-84BB-93501AE1E9A1

P304

Q28263800-7BF45A6B-F9E7-4900-8E4C-7E97350D73AF

P31

Q28263800-7D2E0CF9-3B7F-48A8-9E47-BB840A1FBFFB

P3181

Q28263800-2C85923F-C790-4805-8249-A9BBA3E83C1E

P356

Q28263800-49005332-11DC-4F6C-8E1F-FAAA07B4EB56

P407

Q28263800-F1E708CB-E762-4B3E-8EA5-8D26BD105CDE

P433

Q28263800-37125782-AC23-4587-BC74-0AC720567619

P478

Q28263800-DE885AA2-BF01-4516-9E6D-2A4A613B3A57

P50

Q28263800-E3A54BA0-0D7A-436F-9A94-F2291F1B1D03

P577

Q28263800-44BB7B06-274A-4000-9FE1-B4C515AA6DB1

P5875

Q28263800-761DA037-BF49-4E06-9842-2B7EAC430F86

P698

Q28263800-C90F7E49-0B70-438D-8EFF-E43E7241DC4B

P921

Q28263800-5C33E4CC-03B2-49B4-83DC-FC9CBA7F55D7

Q28263800-DE761172-B4D8-4DF0-993B-C0E504B71286

P3181

P356

BLOOD-2004-03-1091

P1433

P1476

Antitumor activity of rituxima ...... efractory mantle cell lymphoma

@en

P2093

Alexander Bankier

http://www.w3.org/2001/XMLSchema#string

Andreas Chott

http://www.w3.org/2001/XMLSchema#string

Christoph Zielinski

http://www.w3.org/2001/XMLSchema#string

Hannes Kaufmann

http://www.w3.org/2001/XMLSchema#string

Johannes Drach

http://www.w3.org/2001/XMLSchema#string

Markus Raderer

http://www.w3.org/2001/XMLSchema#string

Stefan Wöhrer

http://www.w3.org/2001/XMLSchema#string

P304

2269-71

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P3181

4883753

http://www.w3.org/2001/XMLSchema#string

P356

10.1182/BLOOD-2004-03-1091

http://www.w3.org/2001/XMLSchema#string

P407

P433

8

http://www.w3.org/2001/XMLSchema#string

P478

104

http://www.w3.org/2001/XMLSchema#string

P50

Andreas Püspök

P577

2004-10-15T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

8540514

http://www.w3.org/2001/XMLSchema#string

P698

15166030

http://www.w3.org/2001/XMLSchema#string

P921